Last reviewed · How we verify
Infergen and ribavirin
Infergen (interferon alfacon-1) is a synthetic interferon that activates innate immune responses to inhibit viral replication, while ribavirin is a nucleoside analog that directly inhibits viral RNA synthesis.
Infergen (interferon alfacon-1) is a synthetic interferon that activates innate immune responses to inhibit viral replication, while ribavirin is a nucleoside analog that directly inhibits viral RNA synthesis. Used for Chronic hepatitis C virus infection.
At a glance
| Generic name | Infergen and ribavirin |
|---|---|
| Sponsor | Kadmon Corporation, LLC |
| Drug class | Interferon alpha and nucleoside analog combination |
| Target | Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Infergen is a recombinant type I interferon that binds to interferon-alpha receptors on cell surfaces, triggering antiviral and immunomodulatory pathways including activation of natural killer cells and upregulation of MHC molecules. Ribavirin is a guanosine analog that inhibits viral RNA-dependent RNA polymerase and depletes cellular guanosine triphosphate pools, reducing viral replication. Together, they provide complementary antiviral mechanisms for treating chronic hepatitis C.
Approved indications
- Chronic hepatitis C virus infection
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Hemolytic anemia
- Neutropenia
- Thrombocytopenia
- Depression and psychiatric effects
- Thyroid dysfunction
- Headache
- Nausea
Key clinical trials
- Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (PHASE3)
- Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C (PHASE3)
- Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C
- Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial (PHASE3)
- A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C (PHASE2)
- Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C (PHASE3)
- Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin (PHASE4)
- Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infergen and ribavirin CI brief — competitive landscape report
- Infergen and ribavirin updates RSS · CI watch RSS
- Kadmon Corporation, LLC portfolio CI